Novartis AG
LSE:0K9E
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Novartis AG
LSE:0K9E
|
CH |
|
Z
|
Zoetis Inc
F:ZOE
|
US |
|
C
|
Citizens Financial Group Inc
LSE:0HYP
|
US |
|
FIRST BANK (Hamilton)
NASDAQ:FRBA
|
US |
|
N
|
Nice Ltd
TASE:NICE
|
IL |
|
Equinor ASA
OTC:STOHF
|
NO |
|
Runben Biotechnology Co Ltd
SSE:603193
|
CN |
|
Liberty Media Corp
OTC:LLYVB
|
US |
|
S
|
Subsea 7 SA
XBER:SOC
|
UK |
|
U
|
Unilever PLC
AEX:UNA
|
UK |
Wall St Price Targets
0K9E Price Targets Summary
Novartis AG
According to Wall Street analysts, the average 1-year price target for 0K9E is 158.65 USD with a low forecast of 117.18 USD and a high forecast of 187.42 USD.
Price Targets
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is 0K9E's stock price target?
Price Target
158.65
USD
According to Wall Street analysts, the average 1-year price target for 0K9E is 158.65 USD with a low forecast of 117.18 USD and a high forecast of 187.42 USD.
What is the Revenue forecast for Novartis AG?
Projected CAGR
2%
Over the last 13 years, the compound annual growth rate for Revenue has been 0%. The projected CAGR for the next 8 years is 2%.
What is the Operating Income forecast for Novartis AG?
Projected CAGR
6%
Over the last 13 years, the compound annual growth rate for Operating Income has been 4%. The projected CAGR for the next 8 years is 6%.
What is the Net Income forecast for Novartis AG?
Projected CAGR
7%
Over the last 13 years, the compound annual growth rate for Net Income has been 3%. The projected CAGR for the next 8 years is 7%.
